News Roundup: March 27-31
Your weekly roundup of the latest news from Drug Topics®.
Higher Dose of Oral Semaglutide More Effective for Patients With T2D
According to a recent study, the diabetes medication semaglutide is more effective as a 25 mg or 50 mg dose on its own, rather than a 14 mg add-on dose with other medications.
Rezafungin for Injection to Treat Candidemia and Invasive Candidiasis Gets FDA Approval
The drug, branded as Rezzayo, is the first FDA-approved invasive candidiasis treatment in over a decade.
Studying the Impact of Automated Insulin Delivery on Patients With Type 1 and Type 2 Diabetes
Two posters presented at APhA in Phoenix examined the efficacy of the Omnipod® 5 Automated Insulin Delivery System.
Pharmacy Practitioners Describe Experiences With COVID-19 Misinformation
COVID-19 misinformation is common. A study presented at the annual APhA meeting examined how new pharmacy practitioners responded to misinformation and tried to minimize its spread.
Video: Tips for Medication Management During Ramadan
Pharmacists can provide support and guidance to patients during their month of fasting.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
